7. SciClone Pharmaceuticals ( SCLN) is a global pharmaceutical company engaged in acquiring, developing and commercializing specialist drugs, including drugs for the treatment of cancer and infectious diseases.
For 2010 fourth quarter, earnings per share were 8 cents, compared to 5 cents per share in the year-ago period. For the full year, earnings per share are forecast at 44 cents for 2010, compared to earnings of 25 cents per share for 2009 and a loss of 18 cents per share for 2008. The stock is currently trading at an attractive forward price-to-earnings multiple of 8.6. In comparison, Merck, Gilead Sciences ( GILD), Biogen Idec and Par Pharmaceutical ( PRX) have PE multiples of 10.0, 9.7, 11.5, and 12.1, respectively. All the five analysts covering stock, recommend buying. Analysts polled by Bloomberg anticipate the stock to gain around 49% over the next 12 months with a consensus target price of $6.0.